OptiRTP Presents to Utah Governor’s Delegation at AmCham Briefing
OptiRTP CEO Jon Doherty presented the company’s Optimum Bio Sound Therapy (OBST) platform to a Utah state delegation led by Governor Spencer J. Cox at an AmCham business briefing held during Auckland Start-Up Week on 20 October 2025.
The delegation included senior representatives from Utah’s business, innovation, higher education, and government sectors.
The presentation covered OptiRTP’s planned U.S. operational headquarters, its clinical validation program being developed under the CMS “Coverage with Evidence Development” framework, and its planned FDA De Novo request for Class II.
Following the briefing, CEO Jon Doherty and Founder and Director Bogdan Anich met with representatives from Bank of America, the University of Utah, and other Utah-based organisations to discuss potential support for OptiRTP’s U.S. establishment.
Utah is one of several states OptiRTP will visit in Q1 2026 as part of its U.S. site selection process.
About OptiRTP
OptiRTP (Return to Play) is a New Zealand-based biotech company. Its core technology, OBST (Optimum Bio Sound Therapy), has 352,000+ documented therapy hours with zero serious adverse events reported. OBST is an FDA-registered Class I medical device, 510(k)-exempt (registration and listing, not FDA clearance or approval), that uses dynamic, patterned acoustic neuromodulation via the auditory pathway, with a proposed mechanism involving modulation of central autonomic regulatory networks associated with sleep, pain, recovery and stress regulation. Drug-free and non-invasive, used passively during sleep or rest through a tablet and earbuds. Users can follow recovery markers on their own wearable.
